{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:14:52Z","timestamp":1753877692373,"version":"3.41.2"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":177,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharmaceuticals","award":["grant 513540"],"award-info":[{"award-number":["grant 513540"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>PsA and AS are chronic diseases associated with significant morbidities. National and international management guidelines include treatment with biologic therapies to improve outcomes and quality of life. There are limited real-world data on the patients\u2019 journey from symptom onset to diagnosis and treatment in the UK. We use real-life, linked health data to explore patient pathways and the impact of biologics on patient outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from the Secure Anonymised Information Linkage databank in Wales were used to assess diagnosis and treatment of patients \u226518\u2009years of age with at least one International Classification of Diseases, Tenth Revision code present for PsA\/AS in rheumatology clinic data and at least one Read code present in primary care records. We investigated the use of biologics while exploring demographics, comorbidities and surgical procedures of 641 AS patients and 1312 PsA patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>AS patients were significantly younger at diagnosis and were predominantly male. The average time from presenting symptoms to diagnosis of AS and PsA was 7.9 (s.d. 5.5) and 9.3 (s.d. 5.5)\u2009years, respectively. The proportion of patients receiving biologic treatment was significantly higher in AS (46%) compared with PsA patients (28.8%); of these, 23.1% of AS and 22.2% of PsA patients stopped\/switched a biologic. There was a significant reduction in primary care involvement, sick notes and disability living allowance for both AS and PsA patients following biologic initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This real-world descriptive study confirms that patients treated with biologics have reduced disability and time off work despite being initiated \u223c13\u2009years after the first symptoms and 6\u2009years after diagnosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkab042","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T07:14:18Z","timestamp":1624778058000},"source":"Crossref","is-referenced-by-count":3,"title":["Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-9373","authenticated-orcid":false,"given":"Roxanne","family":"Cooksey","sequence":"first","affiliation":[{"name":"Division of Infection and Immunity, CREATE Centre, Section of Rheumatology, School of Medicine, Cardiff University, Cardiff"},{"name":"Health Data Research UK, Swansea University Medical School, Swansea"},{"name":"National Centre for Population Health and Wellbeing Research, Swansea, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Azizur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Cardiff School of Technologies, Cardiff Metropolitan University, Cardiff, Wales"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Health Data Research UK, Swansea University Medical School, Swansea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinead","family":"Brophy","sequence":"additional","affiliation":[{"name":"Health Data Research UK, Swansea University Medical School, Swansea"},{"name":"National Centre for Population Health and Wellbeing Research, Swansea, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-8609","authenticated-orcid":false,"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, CREATE Centre, Section of Rheumatology, School of Medicine, Cardiff University, Cardiff"},{"name":"National Centre for Population Health and Wellbeing Research, Swansea, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"key":"2021072413210832700_rkab042-B1","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.36740\/WLek201909102","article-title":"Reasons for diagnostic delays of axial spondyloarthritis","volume":"72","author":"Zwolak","year":"2019","journal-title":"Wiad Lek"},{"key":"2021072413210832700_rkab042-B2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40744-019-0153-7","article-title":"Real-world patient experience on the path to diagnosis of ankylosing spondylitis","volume":"6","author":"Ogdie","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2021072413210832700_rkab042-B3","first-page":"2283","article-title":"Delay to diagnosis in axial spondyloarthritis: Are we improving in the UK?","volume":"54","author":"Sykes","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2021072413210832700_rkab042-B4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021072413210832700_rkab042-B5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/ard.2009.116764","article-title":"Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost","volume":"69","author":"Boonen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021072413210832700_rkab042-B6","doi-asserted-by":"crossref","first-page":"e000680","DOI":"10.1136\/rmdopen-2018-000680","article-title":"Employment and the role of personal factors among patients with ankylosing spondylitis: A Dutch cross-sectional case-control study","volume":"4","author":"Webers","year":"2018","journal-title":"RMD Open"},{"key":"2021072413210832700_rkab042-B7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/acr.22730","article-title":"Work outcome in patients with ankylosing spondylitis: results from a 12-year followup of an international study","volume":"68","author":"Castillo-Ortiz","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2021072413210832700_rkab042-B8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","article-title":"Work disability in psoriatic arthritis: a systematic review","volume":"51","author":"Tillett","year":"2012","journal-title":"Rheumatology"},{"key":"2021072413210832700_rkab042-B9","first-page":"4","article-title":"The burden of ankylosing spondylitis","volume":"78","author":"Boonen","year":"2006","journal-title":"J Rheumatol Suppl"},{"key":"2021072413210832700_rkab042-B10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ncprheum0297","article-title":"A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis","volume":"2","author":"Boonen","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2021072413210832700_rkab042-B11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/1529-0131(200110)45:5<424::AID-ART361>3.0.CO;2-7","article-title":"Work disability among people with ankylosing spondylitis","volume":"45","author":"Barlow","year":"2001","journal-title":"Arthritis Care Res"},{"key":"2021072413210832700_rkab042-B12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10067-008-1019-5","article-title":"Variables related to utility in patients with ankylosing spondylitis","volume":"28","author":"Ariza-Ariza","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2021072413210832700_rkab042-B13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.23523","article-title":"Impact of ankylosing spondylitis on work and family life: comparisons with the US population","volume":"59","author":"Ward","year":"2008","journal-title":"Arthritis Care Res"},{"key":"2021072413210832700_rkab042-B14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13075-016-0977-2","article-title":"Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey","volume":"18","author":"Ramonda","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021072413210832700_rkab042-B15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/ard.2008.092049","article-title":"Work disability and health-related quality of life in males and females with psoriatic arthritis","volume":"68","author":"Wallenius","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021072413210832700_rkab042-B16","first-page":"721","article-title":"Employment across chronic inflammatory rheumatic diseases and comparison with the general population","volume":"32","author":"Mau","year":"2005","journal-title":"J Rheumatol"},{"year":"2016","author":"National Institute for Health and Clinical Excellence. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. TA383. London: National Institute for Health and Clinical Excellence","key":"2021072413210832700_rkab042-B17"},{"year":"2010","author":"National Institute for Health and Clinical Excellence","key":"2021072413210832700_rkab042-B18"},{"key":"2021072413210832700_rkab042-B19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021072413210832700_rkab042-B20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/rheumatology\/kes026","article-title":"Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis","volume":"51","author":"Baraliakos","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2021072413210832700_rkab042-B21","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bmj.300.6732.1092","article-title":"The Read clinical classification","volume":"300","author":"Chisholm","year":"1990","journal-title":"BMJ"},{"key":"2021072413210832700_rkab042-B22","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1136\/annrheumdis-2013-204867","article-title":"Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry","volume":"74","author":"S\u00f8rensen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021072413210832700_rkab042-B23","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3899\/jrheum.090481","article-title":"Work disability in patients with ankylosing spondylitis","volume":"36","author":"Ariza-Ariza","year":"2009","journal-title":"J Rheumatol"},{"key":"2021072413210832700_rkab042-B24","doi-asserted-by":"crossref","first-page":"e000766","DOI":"10.1136\/rmdopen-2018-000766","article-title":"Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study","volume":"4","author":"Webers","year":"2018","journal-title":"RMD Open"},{"key":"2021072413210832700_rkab042-B25","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2018-213590","article-title":"Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis","volume":"77","author":"Shim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021072413210832700_rkab042-B26","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3899\/jrheum.100099","article-title":"Cost of illness from the public payers\u2019 perspective in patients with ankylosing spondylitis in rheumatological care","volume":"37","author":"Str\u00f6mbeck","year":"2010","journal-title":"J Rheumatol"},{"key":"2021072413210832700_rkab042-B27","doi-asserted-by":"crossref","first-page":"e0126105","DOI":"10.1371\/journal.pone.0126105","article-title":"The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data","volume":"10","author":"Cooksey","year":"2015","journal-title":"PLoS One"},{"key":"2021072413210832700_rkab042-B28","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1136\/annrheumdis-2012-201914","article-title":"Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review","volume":"71","author":"van der Burg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021072413210832700_rkab042-B29","first-page":"603","article-title":"Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis","volume":"56","author":"Tillett","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2021072413210832700_rkab042-B30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/annrheumdis-2014-205198","article-title":"Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study","volume":"74","author":"Kavanaugh","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021072413210832700_rkab042-B31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/03009742.2018.1444199","article-title":"Biological treatment in ankylosing spondylitis in the Nordic countries during 2010\u20132016: a collaboration between five biological registries","volume":"47","author":"Glintborg","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2021072413210832700_rkab042-B32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00296-018-4195-x","article-title":"Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe","volume":"39","author":"Gottlieb","year":"2019","journal-title":"Rheumatol Int"},{"key":"2021072413210832700_rkab042-B33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/cer-2017-0076","article-title":"Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database","volume":"7","author":"Walsh","year":"2018","journal-title":"J Comp Eff Res"},{"key":"2021072413210832700_rkab042-B34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/art.20233","article-title":"The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index","volume":"51","author":"Heuft-Dorenbosch","year":"2004","journal-title":"Arthritis Care Res"},{"key":"2021072413210832700_rkab042-B35","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3899\/jrheum.101049","article-title":"Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease","volume":"38","author":"P\u00e9rez Alamino","year":"2011","journal-title":"J Rheumatol"},{"key":"2021072413210832700_rkab042-B36","article-title":"Predicting a diagnosis of ankylosing spondylitis using primary care health records \u2013 a machine learning approach","author":"Kennedy","year":"2021","journal-title":"medRxiv"},{"key":"2021072413210832700_rkab042-B37","doi-asserted-by":"crossref","first-page":"11580","DOI":"10.1038\/s41598-020-68456-7","article-title":"Prevalence of sacroiliitis and acute and structural changes on MRI in patients with psoriatic arthritis","volume":"10","author":"Braga","year":"2020","journal-title":"Sci Rep"},{"key":"2021072413210832700_rkab042-B38","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021072413210832700_rkab042-B39","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor \u03b1","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"2021072413210832700_rkab042-B40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00228-014-1706-x","article-title":"Impact of biological therapy on spondyloarthritis","volume":"70","author":"Maruotti","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2021072413210832700_rkab042-B41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3899\/jrheum.100698","article-title":"Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial","volume":"38","author":"Gladman","year":"2011","journal-title":"J Rheumatol"},{"key":"2021072413210832700_rkab042-B42","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/acr.22044","article-title":"Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial","volume":"65","author":"Kavanaugh","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2021072413210832700_rkab042-B43","first-page":"2254","article-title":"Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis","volume":"33","author":"Kavanaugh","year":"2006","journal-title":"J Rheumatol"},{"key":"2021072413210832700_rkab042-B44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/rheumatology\/ken010","article-title":"Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis","volume":"47","author":"Keat","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2021072413210832700_rkab042-B45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0000000000000229","article-title":"An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies","volume":"21","author":"Bandr\u00e9s Ciga","year":"2015","journal-title":"J Clin Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkab042\/38830332\/rkab042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/2\/rkab042\/39307450\/rkab042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/2\/rkab042\/39307450\/rkab042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T13:21:38Z","timestamp":1627132898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkab042\/6310184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkab042","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2021]]},"published":{"date-parts":[[2021]]},"article-number":"rkab042"}}